52730-01-5 Usage
Uses
Used in Pharmaceutical and Agrochemical Industries:
(S)-Quinuclidine-2-carboxylic acid hydrochloride is used as a chiral building block for the synthesis of pharmaceuticals and agrochemicals. Its unique structure allows for the creation of enantiomerically pure compounds, which is crucial for the development of effective and safe drugs and agrochemicals.
Used in the Treatment of Neurological Disorders:
(S)-Quinuclidine-2-carboxylic acid hydrochloride is studied for its potential applications in the treatment of neurological disorders. Its ability to interact with specific biological targets makes it a promising candidate for the development of therapeutic agents targeting the central nervous system.
Used as a Catalyst in Asymmetric Synthesis:
(S)-Quinuclidine-2-carboxylic acid hydrochloride is utilized as a catalyst in asymmetric synthesis, a technique that allows for the selective formation of one enantiomer over another. This is particularly important in the synthesis of chiral compounds, where the desired biological activity is often associated with a specific enantiomer.
Used in Research and Development:
The hydrochloride salt form of (S)-Quinuclidine-2-carboxylic acid is used in research and development due to its enhanced water solubility and stability. This makes it suitable for a wide range of applications, including the synthesis of new compounds, the study of biological interactions, and the development of novel drug delivery systems.
Check Digit Verification of cas no
The CAS Registry Mumber 52730-01-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,7,3 and 0 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 52730-01:
(7*5)+(6*2)+(5*7)+(4*3)+(3*0)+(2*0)+(1*1)=95
95 % 10 = 5
So 52730-01-5 is a valid CAS Registry Number.
52730-01-5Relevant academic research and scientific papers
Kurasawa, Osamu,Miyazaki, Tohru,Homma, Misaki,Oguro, Yuya,Imada, Takashi,Uchiyama, Noriko,Iwai, Kenichi,Yamamoto, Yukiko,Ohori, Momoko,Hara, Hideto,Sugimoto, Hiroshi,Iwata, Kentaro,Skene, Robert,Hoffman, Isaac,Ohashi, Akihiro,Nomura, Toshiyuki,Cho, Nobuo
, p. 1084 - 1104 (2020)
In our pursuit of developing a novel, potent, and selective cell division cycle 7 (Cdc7) inhibitor, we optimized the previously reported thieno[3,2-d]pyrimidinone analogue I showing time-dependent Cdc7 kinase inhibition and slow dissociation kinetics. These medicinal chemistry efforts led to the identification of compound 3d, which exhibited potent cellular activity, excellent kinase selectivity, and antitumor efficacy in a COLO205 xenograft mouse model. However, the issue of formaldehyde adduct formation emerged during a detailed study of 3d, which was deemed an obstacle to further development. A structure-based approach to circumvent the adduct formation culminated in the discovery of compound 11b (TAK-931) possessing a quinuclidine moiety as a preclinical candidate. In this paper, the design, synthesis, and biological evaluation of this series of compounds will be presented.
